In just 30 days, a potential cancer treatment has been developed through the use of artificial intelligence, which also has the capability to predict a patient’s survival rate.
The University of Toronto, along with Insilico Medicine, published a study in the Chemical Science journal, detailing the development of a new treatment for hepatocellular carcinoma (HCC), the most common type of liver cancer, the New York Post reported.
Using an AI drug discovery platform called Pharma.AI, the researchers applied AlphaFold, an AI-powered protein structure database, to identify a previously unknown treatment pathway for cancer.
They then synthesized just seven compounds to create a “novel hit molecule” that could bind to the target without assistance.
Following a subsequent round of compound generation, a more powerful hit molecule was discovered. However, before any potential medication can be widely employed, it would need to undergo clinical trials.
Written by staff